[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundación Academia Española de Dermatología\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100491097","spanish-academy-of-dermatology-and-venereology-registry-of-atopic-dermatitis-therapy-100491097",false,"NCT05674695","Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy","BIOBADATOP","Inclusion Criteria:\n\n1. Paediatric and adult patients with atopic eczema who due to the severity of their disease and\u002For impact on quality of life are commencing on or switching to a specific systemic immuno-modulatory agent (e.g. CyA, AZA, MTX or new\u002Fbiologic treatments) for the first time in their life (might have received others, but not this specific one).\n2. Diagnosis of atopic eczema in keeping with the UK\u002FIrish diagnostic criteria.\n3. Willingness to comply with all study requirements.\n\nExclusion Criteria:\n\n1. Insufficient understanding of the study by the patient and\u002For parent\u002Fguardian.\n2. Patients who are currently participating in a randomised clinical trial.\n3. Intention to move to a different geographical area in a short-term (next 3 months).","ALL",{"count":18,"type":19},2500,"ESTIMATED","5 Years","OBSERVATIONAL","The Spanish Registry of Systemic therapy in atopic eczema, BIOBADATOP, assesses drug safety and treatment effectiveness as well as treatment impact on quality of life in children and adults with atopic eczema receiving systemic immuno-modulatory therapies in Spanish daily practice.\n\nThe main objectives are:\n\n1. To assess short and long-term safety of systemic therapies (including phototherapy) for atopic eczema (pharmacovigilance).\n2. To assess short and long-term effectiveness of systemic therapies, providing a basis for shared decision making and guidelines.\n\nSecondary objectives are:\n\n1. To assess short and long-term safety of topical therapies for atopic eczema.\n2. To assess effectiveness of different methods of care, including patient training.\n3. To describe atopic dermatitis comorbidities.",[24],"Dermatitis, Atopic","RECRUITING","2023-01-05",{"date":28,"type":29},"2023-01-06","ACTUAL",{"date":31,"type":29},"2019-01-01",{"date":33,"type":19},"2029-01-01",{"name":35,"class":36},"Fundación Academia Española de Dermatología","OTHER",9,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":45,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":57},"100491019","spanish-academy-of-dermatology-and-venereology-aedv-melanoma-registry-100491019","NCT05673681","Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry","Registro de Melanoma de la AEDV","Inclusion Criteria:\n\n* All consecutive patients with a diagnosis of invasive primary cutaneous melanoma in participating centres.\n\nExclusion Criteria:\n\n* In-situ melanomas\n* non-cutaneous melanomas,\n* metastatic melanoma with unknown primary site.",{"count":46,"type":19},7000,"The goal of this patient registry is to describe risk factors for bad prognosis of melanoma in Spain. The main questions it aims to answer are:\n\n* To describe socioeconomical individual risk factors associated with melanoma prognosis, such as gender, residence area or socioeconomic level.\n* To describe potentially modifiable characteristics of health care associated with prognosis, such as waiting times, type of centre that makes the diagnosis or use of teledermatology Participants data will be gathered for analysis, without any change in the way that they are being treated.",[49],"Melanoma",{"date":51,"type":29},"2023-01-09",{"date":53,"type":29},"2022-06-01",{"date":55,"type":19},"2032-06-01",{"name":35,"class":36},21,""]